GB9820014D0 - Receptor antagonists and uses thereof - Google Patents

Receptor antagonists and uses thereof

Info

Publication number
GB9820014D0
GB9820014D0 GBGB9820014.0A GB9820014A GB9820014D0 GB 9820014 D0 GB9820014 D0 GB 9820014D0 GB 9820014 A GB9820014 A GB 9820014A GB 9820014 D0 GB9820014 D0 GB 9820014D0
Authority
GB
United Kingdom
Prior art keywords
receptor antagonists
antagonists
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9820014.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Campaign Technology Ltd
Original Assignee
Cancer Research Campaign Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Campaign Technology Ltd filed Critical Cancer Research Campaign Technology Ltd
Priority to GBGB9820014.0A priority Critical patent/GB9820014D0/en
Publication of GB9820014D0 publication Critical patent/GB9820014D0/en
Priority to AU58757/99A priority patent/AU5875799A/en
Priority to PCT/GB1999/003059 priority patent/WO2000015663A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
GBGB9820014.0A 1998-09-14 1998-09-14 Receptor antagonists and uses thereof Ceased GB9820014D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB9820014.0A GB9820014D0 (en) 1998-09-14 1998-09-14 Receptor antagonists and uses thereof
AU58757/99A AU5875799A (en) 1998-09-14 1999-09-14 Mip-1alpha isoform ld78beta and uses thereof
PCT/GB1999/003059 WO2000015663A1 (en) 1998-09-14 1999-09-14 MIP-1α ISOFORM LD78β AND USES THEREOF

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9820014.0A GB9820014D0 (en) 1998-09-14 1998-09-14 Receptor antagonists and uses thereof

Publications (1)

Publication Number Publication Date
GB9820014D0 true GB9820014D0 (en) 1998-11-04

Family

ID=10838848

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9820014.0A Ceased GB9820014D0 (en) 1998-09-14 1998-09-14 Receptor antagonists and uses thereof

Country Status (3)

Country Link
AU (1) AU5875799A (en)
GB (1) GB9820014D0 (en)
WO (1) WO2000015663A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235143B2 (en) 2002-08-08 2007-06-26 Praxair S.T. Technology, Inc. Controlled-grain-precious metal sputter targets
SG10201404273QA (en) 2003-12-23 2014-10-30 Genentech Inc Novel anti-il 13 antibodies and uses thereof
CA2588846A1 (en) * 2004-11-26 2006-12-07 Board Of Regents, The University Of Texas System Methods and compositions for correlating ccl3l1/ccr5 genotypes with disorders
JP2013532971A (en) 2010-06-25 2013-08-22 バッシボディ アクスイェ セルスカプ Homodimeric protein construct
WO2013149186A1 (en) 2012-03-30 2013-10-03 Insulet Corporation Fluid delivery device with transcutaneous access tool, insertion mechansim and blood glucose monitoring for use therewith
MX2016003202A (en) 2013-09-13 2016-06-07 Genentech Inc Methods and compositions comprising purified recombinant polypeptides.
EP3044323B1 (en) 2013-09-13 2022-04-06 F. Hoffmann-La Roche AG Methods for detecting and quantifying host cell protein in cell lines
WO2017091624A1 (en) 2015-11-24 2017-06-01 Insulet Corporation Wearable automated medication delivery system

Also Published As

Publication number Publication date
WO2000015663A1 (en) 2000-03-23
AU5875799A (en) 2000-04-03

Similar Documents

Publication Publication Date Title
EP1100506A4 (en) Integrin receptor antagonists
EP1105389A4 (en) Integrin receptor antagonists
EP1047425A4 (en) Integrin receptor antagonists
EP1007026A4 (en) Integrin antagonists
EP0934305A4 (en) Integrin antagonists
IL143226A0 (en) Pyrrolidine derivatives-ccr-3 receptor antagonists
HU9603525D0 (en) Vironectin receptor antagonists
EP1007051A4 (en) Integrin receptor antagonists
GB2343891B (en) 4-Aroyl-piperidine CCR-3 receptor antagonists
EP0946164A4 (en) Integrin antagonists
EP0880511A4 (en) Integrin receptor antagonists
SG80041A1 (en) Muscarinic receptor antagonists
IL135797A0 (en) Thrombin receptor antagonists
IL138245A0 (en) Vitronectin receptor antagonists
EP1027337A4 (en) Integrin receptor antagonists
GB9820014D0 (en) Receptor antagonists and uses thereof
EP1084142A4 (en) Gpr35a receptor
AU3935897A (en) B1-bradykinin receptor antagonists and use thereof
IL141163A0 (en) Vitronectin receptor antagonists
EP1083909A4 (en) hCEPR RECEPTOR
GB9811283D0 (en) Vironectin receptor antagonists
EP1109565A4 (en) Gabab1aa receptor
GB9603373D0 (en) Integrin receptor antagonists
IL119820A0 (en) Integrin receptor antagonists
ZA986930B (en) Integrin receptor antagonists

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)